ASCO GU 2022
ASCO GU 2022 Prostate Cancer
- ASCO GU 2022: A Path Forward: Addressing Disparities in Genitourinary Cancers
- ASCO GU 2022: Treatment Outcomes for mCRPC Following Progression on Upfront ADT with Androgen Receptor Pathway Inhibitors for mCSPC
- ASCO GU 2022: The TRAP Trial: Targeting Resistant Prostate Cancer, with or without DNA Repair Defects, Using the Combination of Ceralasertib and Olaparib
- ASCO GU 2022: Real-World Health-Related Quality of Life and Caregiver Needs in Patients with mHSPC and mCRPC
- ASCO GU 2022: Real-World Analyses of Major Adverse Cardiovascular Event Risk by Drug Class After Initiation of ADT
ASCO GU 2022 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2022: Endocrine Tumors of the Genitourinary Tract
- ASCO GU 2022: First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients: The ADIUVO Study
- ASCO GU 2022: Clinical Results of PERICLES: A Phase II Trial Investigating Atezolizumab +/- Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis
- ASCO GU 2022: The PRIMETEST Trial: Prospective Phase II Trial of Primary Retroperitoneal Lymph Node Dissection in Stage II A/B Patients With Seminoma
- ASCO GU 2022: Optimization of Serum miR-371a-3p for the Detection of Chemotherapy-Naïve Minimal Residual Germ Cell Tumor
ASCO GU 2022 Press Releases
- Positive Results from Phase III Investigational Trial Shows NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy (ADT) and Docetaxel Significantly Increases Overall Survival (OS) in Patients with mHSPC
- Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
- Biomarker for Bladder Cancer Survival: Results From the SWOG 1314 Clinical Trial
- Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer
- New Genetic Risk Score Stratifies Lifetime Risk of Dying of Prostate Cancer in Diverse Populations
ASCO GU 2022 Bladder Cancer
- ASCO GU 2022: Bladder-Sparing Trimodality Therapy: Toxicity and Functional Outcomes in the Era of Novel Therapeutics
- ASCO GU 2022: First-Line Pembrolizumab with or Without Lenvatinib in Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Study.
- ASCO GU 2022: ABLE: Phase 2, Single-Arm, Two-Stage Study of Nab-Paclitaxel with Anti-PD1/PDL1 in Advanced Urothelial Cancer
- ASCO GU 2022: Biomarker Analysis and Updated Clinical Follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy
- ASCO GU 2022: First-Line Pembrolizumab in Advanced Urothelial Carcinoma: Clinical Parameters Associated with Efficacy in the Phase 2 KEYNOTE-052 and Phase 3 KEYNOTE-361 Trials
ASCO GU 2022 Kidney Cancer
- ASCO GU 2022: Matching Sequencing Reports With Available Therapies in Renal Cell Carcinoma
- ASCO GU 2022: Current Data on Predictive Biomarkers in Renal Cell Carcinoma
- ASCO GU 2022: Germline Mutations of Interests in Renal Cell Carcinoma
- ASCO GU 2022: Adjuvant and Consolidative Therapy in Oligometastatic Renal Cell Carcinoma
- ASCO GU 2022: Updates on Clinical Trials in First-Line Metastatic Renal Cell Carcinoma Plus Novel Pathways and Endpoints
ASCO GU 2022 Upper Tract Urothelial Carcinoma
- ASCO GU 2022: New Evidence to Optimize Bladder Preservation
- ASCO GU 2022: Endoscopic Management of Low-Grade Upper-Tract Urothelial Carcinoma
- ASCO GU 2022: Defining Hereditary Upper Tract Urothelial Carcinoma: Implications for Genetic Testing and Clinical Management
- ASCO GU 2022: Survival Outcomes Comparing Radical Nephroureterectomy Versus Endoscopic Treatment in Solitary Kidney Patients Diagnosed With Upper Tract Urothelial Carcinoma